Aptimmune Biologics develops mucosal vaccines for swine, focusing on PRRSV and influenza virus. The company’s pipeline is built on patented vaccine technologies invented by founder and Chief Scientific Officer Dr. Federico Zuckermann, a swine immunologist and University of Illinois professor. New CEO Aaron Gilbertie, who joined weeks before the financing, will lead pipeline development, product registration, and commercialization. Management says the vaccines will improve swine health and producer productivity and address diseases with a combined annual economic impact of over $1.4 billion on the U.S. swine industry. Aptimmune is based in the EnterpriseWorks technology business incubator at the University of Illinois Research Park in Champaign, Ill. The company reports a strong and extensive intellectual property portfolio underpinning its product offerings. The recent funding is intended to accelerate development and product registration of its mucosal vaccine candidates.

Total raised

$3M

Funding rounds

1

Latest round

Series A

Latest activity

Jul 2015